April 1, 2024Open Access

Wcn24-683 Efficacy of 12-Week Pegcetacoplan in Kidney Transplant Recipients With Recurrent C3 Glomerulopathy (C3g) or Immune Complex Membranoproliferative Glomerulonephritis (Ic-Mpgn)

Key Points

Key points are not available for this paper at this time.

Abstract

Pegcetacoplan (PEG; C3 inhibitor) may prevent C3G or IC-MPGN progression. NOBLE (NCT04572854) is the first prospective randomized controlled trial of PEG vs standard of care (SOC) in kidney transplant recipients (KTRs) with primary C3G or IC-MPGN recurrence.

Wcn24-683 Efficacy of 12-Week Pegcetacoplan in Kidney Transplant Recipients With Recurrent C3 Glomerulopathy (C3g) or Immune Complex Membranoproliferative Glomerulonephritis (Ic-Mpgn)

Key Points

Abstract

Cite This Study

Also Consider

Also Consider